A Study Of The Mechanism Of Origin In Germ Cell Tumor-associated Hematologic Malignancies

Overview

About this study

The purpose of this study is to characterize the mechanism of origin of GCT-associated hematologic malignancies through comprehensive cytogenetic and molecular genetic testing of specimens representing the hematologic malignancy, GCT tissue, and unaffected tissue (for germline component subtraction).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients should have sufficient cytogenetics/molecular genetics, and/or clinical information evidence to suggest a concurrent presence of a GCT and a hematologic malignancy.

 Exclusion Criteria:

  • Patients with isolated presence of a GCT or hematologic malignancy with no internal or external indication of co-occurrence

  • Blood transfusion within the past two weeks

  • Previous bone marrow transplant (unless affected samples obtained prior to transplant)

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 03/23/2026. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Patricia Greipp, D.O.

Contact us for the latest status

Contact information:

RST Biochemical Genetics Laboratory Genetic Counselor

(507) 266-4996

BIOCHEMICALgenetics@mayo.edu

More information

Publications

Publications are currently not available